ProfessionalLive ClassesNo New Dates

Advanced Certificate in Psychedelic Integration

The Certificate in Psychedelic Harm Reduction and Integration equips clinicians with practical skills to support clients before and after psychedelic experiences

Provider

Fluence

English

Schedule

Twelve weeks

Enrollment

$3,000

Course Overview

The Advanced Certificate In Psychedelic Integration is designed to equip clinicians with the skills necessary to support clients before and after psychedelic experiences. This course focuses on practical techniques for harm reduction and integration, helping clients navigate psychedelic experiences, whether they occur in clinical, ceremonial, or recreational contexts. Participants will engage in live online sessions, peer learning, and case-based discussions, providing a robust learning environment.

Over twelve weeks, the course covers various topics including preparation and setting, managing challenging experiences, and integrating insights post-experience. It emphasizes ethical considerations and practical strategies to ensure clients receive comprehensive support. The program includes personalized feedback, video demonstrations, and peer learning opportunities to enhance practical understanding and application.

Clinicians will learn how to integrate psychedelic experiences into their practice, addressing common challenges and promoting positive therapeutic outcomes. By the end of the course, participants will be proficient in applying harm reduction techniques and integration strategies, effectively supporting clients through their psychedelic journeys.

Who is this for?

Clinicians seeking practical training in psychedelic harm reduction and integration.

Prerequisites

null

About the Provider

Fluence is a psychedelic therapy education company co-founded by psychologists Dr. Ingmar Gorman and Dr. Elizabeth Nielson, offering continuing education courses and a Certificate in Psychedelic Therapy and Integration for licensed therapists and advanced graduate students. Having trained 8,000+ clinicians, Fluence draws on its founders' direct experience in FDA-approved Phase 3 clinical trials of MDMA- and psilocybin-assisted therapies.

Related Courses

View all courses